E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.

File(s)

Claudiani S et al - Haematologica 2017.pdf (181.96 KB)

Published version

Show more

Author(s)

Claudiani, S

Apperley, J

Gale, RP

Clark, R

Szydlo, R

more

Type

Journal Article

Date Issued

2017-05-11

Date Acceptance

2017-05-01

Citation

Haematologica, 2017, 102 (8), pp.e297-e299

URI

http://hdl.handle.net/10044/1/49044

DOI

https://www.dx.doi.org/10.3324/haematol.2017.168740

ISSN

0390-6078

Publisher

Ferrata Storti Foundation

Start Page

e297

End Page

e299

Journal / Book Title

Haematologica

Volume

102

Issue

8

Copyright Statement

© 2017 Ferrata Storti Foundation. Haematologica August 2017 102: e297-e299; Doi:10.3324/haematol.2017.168740. Open Access under the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/)

Sponsor

Imperial College Trust

Imperial College Healthcare NHS Trust- BRC Funding

National Institute for Health Research

Imperial College Healthcare NHS Trust

Identifier

http://www.ncbi.nlm.nih.gov/pubmed/28495914

PII: haematol.2017.168740

Grant Number

070904JA

RDB05 79560

NF-SI-0611-10275

IPH-RMO-HH/004

Subjects

Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders

Minimal Residual Disease

Stopping TKI

Treatment free remission

Immunology

1102 Cardiovascular Medicine And Haematology

Publication Status

Published

Coverage Spatial

Italy